Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Halozyme Therapeutics Inc. Common Stock (HALO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Halozyme Therapeutics Inc. Common Stock — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B), while Halozyme Therapeutics Inc. Common Stock trades at $117.12 (market cap $12.44B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 2.5× Halozyme Therapeutics Inc. Common Stock's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals.
| GEHC | HALO | |
|---|---|---|
Market Cap | $31.07B | $12.44B |
Volume | 3,443,020 | 1,772,623 |
Sector | Health | Health |
52-Week High | $88.16 | $116.82 |
52-Week Low | $59.48 | $61.63 |
Enterprise Value | $39.53B | $14.36B |
Dividend Yield | 0.23% | — |
Typical Hold Time | — | 1 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Halozyme Therapeutics (HALO) trades at $109.62, down 1.31% today but near its recent highs. The stock shows strong fundamental momentum with revenue growth from $1.4B in 2025 to $1.7B projected for 2026 and net income margins improving to 24.85%. Recent positive developments include a patent win against Merck in Europe and an expanded collaboration with argenx, enhancing its ENHANZE technology revenue streams. Technical indicators are bullish on moving averages, though oscillators signal neutrality with RSI at 73 suggesting overbought conditions. Support is firm at $107 with resistance at $112.
HALO presents a growth opportunity driven by robust financials and strategic expansions, but risks include high valuation multiples (P/E 32.15, P/B 86.68) and insider selling by the CEO. Analyst consensus is strongly bullish with 66.7% buy ratings and a $106 price target, though the current price exceeds this, indicating potential near-term consolidation. Investors should weigh solid earnings beats against elevated expectations and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →
